Format
Sort by

Send to

Choose Destination

Search results

Items: 20

1.

Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.

Hwang SJ, Anforth R, Carlos G, Fernandez-Peñas P.

Actas Dermosifiliogr. 2017 Jan - Feb;108(1):6-16. doi: 10.1016/j.ad.2016.05.019. English, Spanish.

PMID:
27642030
2.

Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.

Ali M, Anforth R, Senetiner F, Carlos G, Fernandez-Penas P.

Exp Dermatol. 2016 May;25(5):394-5. doi: 10.1111/exd.12975. No abstract available.

PMID:
26896751
3.

Treatment-specific utility weightings are needed for cost-utility analysis in metastatic melanoma.

Sebaratnam DF, Anforth R, Fernández-Peñas P.

Br J Dermatol. 2016 Feb;174(2):462-3. doi: 10.1111/bjd.14264. No abstract available.

PMID:
26523742
4.

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.

Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, Fernandez-Peñas P.

JAMA Dermatol. 2015 Oct;151(10):1103-9. doi: 10.1001/jamadermatol.2015.1745.

PMID:
26200476
5.

Tinea hidden by a vemurafenib-induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone.

Anforth R, Carlos G, Eiris N, Clements A, Fernandez-Peñas P.

Med J Aust. 2015 Jul 6;203(1):41-2. No abstract available.

PMID:
26126567
6.

A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.

Carlos G, Anforth R, Chou S, Clements A, Fernandez-Peñas P.

Melanoma Res. 2015 Jun;25(3):265-8. doi: 10.1097/CMR.0000000000000155.

PMID:
25831416
7.

Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.

Anforth R, Menzies A, Byth K, Carlos G, Chou S, Sharma R, Scolyer RA, Kefford R, Long GV, Fernandez-Peñas P.

J Am Acad Dermatol. 2015 May;72(5):809-15.e1. doi: 10.1016/j.jaad.2015.01.018.

PMID:
25748298
8.

Dabrafenib-associated necrobiotic granulomatous reaction.

Carlos G, Anforth R, Chou S, Fernandez-Peñas P.

Australas J Dermatol. 2014 Nov;55(4):306-8. doi: 10.1111/ajd.12226. No abstract available.

PMID:
25399793
9.

Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.

Anforth RM, Carlos GR, Scolyer RA, Chou S, Fernandez-Peñas P.

Melanoma Res. 2015 Feb;25(1):91-4. doi: 10.1097/CMR.0000000000000127.

PMID:
25380183
10.

Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.

Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Peñas P.

Br J Dermatol. 2015 Jan;172(1):239-43. doi: 10.1111/bjd.13200.

PMID:
25040674
11.

Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.

Uribe P, Anforth RM, Kefford RF, Fernandez-Peñas P.

Melanoma Res. 2014 Oct;24(5):501-3. doi: 10.1097/CMR.0000000000000096.

PMID:
24922191
12.

Panniculitis in patients treated with BRAF inhibitors: a case series.

Choy B, Chou S, Anforth R, Fernández-Peñas P.

Am J Dermatopathol. 2014 Jun;36(6):493-7. doi: 10.1097/DAD.0000000000000023.

PMID:
24879511
13.

Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.

Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, Long GV, Fernandez-Peñas P.

Australas J Dermatol. 2014 Nov;55(4):250-4. doi: 10.1111/ajd.12124.

PMID:
24313958
14.

Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.

Anforth R, Blumetti TC, Clements A, Kefford R, Long GV, Fernandez-Peñas P.

Br J Dermatol. 2013 Dec;169(6):1310-3. doi: 10.1111/bjd.12519.

PMID:
23870055
15.

Non-evolving linear facial plaque.

Mohd Affandi A, Anforth R, Chou S, Fernadez-Peñas P.

Clin Exp Dermatol. 2013 Aug;38(6):681-3. doi: 10.1111/ced.12023. No abstract available.

PMID:
23581846
16.

BRAF inhibitor induced verrucal keratosis.

Anforth R, Fernandez-Penas P.

Am J Dermatopathol. 2014 Feb;36(2):192. doi: 10.1097/DAD.0b013e3182858142. No abstract available.

PMID:
23435364
17.

Cutaneous toxicities of RAF inhibitors.

Anforth R, Fernandez-Peñas P, Long GV.

Lancet Oncol. 2013 Jan;14(1):e11-8. doi: 10.1016/S1470-2045(12)70413-8. Review.

PMID:
23276366
18.

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.

Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, Long GV, Fernandez-Peñas P.

Br J Dermatol. 2012 Nov;167(5):1153-60. doi: 10.1111/j.1365-2133.2012.11155.x.

PMID:
22804352
19.

Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.

Anforth R, Tembe V, Blumetti T, Fernandez-Peñas P.

Pigment Cell Melanoma Res. 2012 Sep;25(5):569-72. doi: 10.1111/j.1755-148X.2012.01031.x.

PMID:
22726224
20.

Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib.

Anforth R, Blumetti TC, Mohd Affandi A, Fernandez-Penas P.

J Clin Oncol. 2012 Jul 1;30(19):e165-7. doi: 10.1200/JCO.2011.39.8594. No abstract available.

PMID:
22665544
Items per page

Supplemental Content

Loading ...
Support Center